Pharmaceuticals Roche continues its growth trajectory in 2025
Roche can look back on a successful financial year 2025. The pharmaceutical company met its own targets and the outlook for the future also promises further growth. However, as usual, the forecast is initially cautious.
29.01.2026, 07:05
29.01.2026, 07:17
SDA
In total, Roche generated sales of 61.5 billion Swiss francs last year, an increase of 2 percent, as the Group announced on Thursday. At constant exchange rates, growth amounted to 7 percent, thus achieving its own target of growth in the mid-single-digit percentage range.
While the Pharmaceuticals division increased its turnover by 3 percent to 47.7 billion, revenue in the Diagnostics business was 3 percent lower at 13.8 billion. In particular, volume-oriented procurement in China slowed growth last year.
Roche reported a net profit of 13.8 billion Swiss francs, compared with 9.2 billion in the previous year. According to Roche, this was due to the strong operating performance and base effects due to impairments in 2024. Core operating profit, which analysts use as a benchmark, rose by 5 percent.
The reported figures are slightly below analysts' average estimates.
As usual, Roche is not venturing too far out of the window when it comes to the outlook for the current financial year 2026. CEO Thomas Schinecker and his management team expect sales to increase by a mid-single-digit percentage at constant exchange rates. Core earnings per share are expected to increase in the high single-digit percentage range.
The Group is also continuing its efforts to increase the dividend in Swiss francs.
For 2025, shareholders are to receive an increased dividend of CHF 9.80 from CHF 9.70.
